Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals' stock price has experienced significant volatility in the past six months. From November 22, 2024, to November 21, 2025, the share price declined by 83.89%, from $27.00 to $4.35. As of November 26, 2025, the stock was trading at $3.75, with a 52-week range between $3.75 and $25.80. On July 31, 2025, Acurx Pharmaceuticals, Inc. announced a reverse stock split. On September 3, 2025, the company regained full compliance with Nasdaq's minimum $1.00 bid price and minimum stockholders' equity rules. The Q2 2025 earnings report, released on August 12, 2025, showed an EPS of -$1.89, beating the estimate of -$2.06, but the stock declined 1.0% the day after the announcement. The Q3 2025 earnings report, released on November 12, 2025, showed an EPS of -$1.23, exceeding the analyst estimate of -$1.54 by 20.13%, but the stock declined 4.12% in premarket trading. News regarding the publication of results from ibezapolstat studies in Nature Communications on November 10, 2025, and the award of a research grant for DNA Pol IIIC Inhibitors on November 18, 2025, may have influenced investor sentiment.

Detailed information regarding specific seasonal trends for Acurx Pharmaceuticals' products and services is not publicly available without specialized access, although there is a mention of identifying "seasonal patterns" and "monthly returns" for ACXP to understand demand seasonality.

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics to combat difficult-to-treat bacterial infections. The company operates within the Health Care sector, specifically in the Biotechnology: Pharmaceutical Preparations industry. Acurx Pharmaceuticals' strategy involves developing antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that target the DNA polymerase IIIC enzyme, inhibiting DNA replication and leading to bacterial cell death. Acurx's lead antibiotic candidate, ibezapolstat, is a novel, orally administered drug in Phase 2b clinical trials for the treatment of Clostridioides difficile infections (CDI) and has received FDA FAST TRACK designation with plans to begin international clinical trials. ACX-375C is a potential oral and parenteral treatment targeting various Gram-positive bacteria. The company also has other early-stage antibiotic candidates in its research and development pipeline.

Acurx Pharmaceuticals, Inc. is headquartered in Staten Island, New York, United States. The company develops antibiotics to treat bacterial infections in the United States and has plans to initiate international clinical trials for its lead candidate, ibezapolstat.

Acurx Pharmaceuticals has seen positive developments that could contribute to its brand reputation, such as the publication of scientific research in Nature Communications and a positive opinion from the EMA on its Pediatric Investigation Plan for Ibezapolstat. The company was also awarded another innovative research grant for DNA Pol IIIC Inhibitors. However, some individual investors have expressed negative sentiment.

Acurx Pharmaceuticals, Inc. has 17 institutional owners and shareholders holding a total of 55,793 shares, including Prospect Financial Services LLC, Susquehanna International Group, Llp, and Sabby Management, Llc. Individual insiders own approximately 6.17% of the company's shares, while institutions hold about 8.09%, and the general public owns roughly 85.7%. Notable individual insiders include David P. Luci (CEO) and Joseph C. Scodari.